Ardent Health Reaffirms FY26 Adj EBITDA Guidance Of $485M-$535M

Commenting on the Company's financial outlook, Alfred Lumsdaine, Chief Financial Officer, said "During the second quarter, we've observed volume softness across our portfolio. We have taken appropriate and decisive action, including accelerating and expanding our IMPACT program. Based on these actions and the current environment, we are reaffirming our full-year 2026 Adjusted EBITDA guidance of $485 to $535 million."